Craig Sieron, OD
Optometrist · Belleville, ILNPI 1669592440
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 29.7% of the total. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $44.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$3K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$808
- Oyster Point Pharma, Inc.$496
- Harrow Eye, LLC$379
- plus $2K from 12 others
What the payments were for
- Travel & lodging$8559%
- Food & beverage$8,53891%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 51 | $2,791 |
| Sun Pharmaceutical Industries Inc. | 41 | $1,246 |
| AbbVie(2 entities) | 24 | $1,245 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $808 |
| Oyster Point Pharma, Inc. | 14 | $496 |
| Harrow Eye, LLC | 15 | $379 |
| Tarsus Pharmaceuticals, Inc. | 11 | $340 |
| Glaukos Corporation | 2 | $276 |
| Shire North American Group Inc | 6 | $270 |
| Kala Pharmaceuticals, Inc. | 3 | $263 |
| Eyevance Pharmaceuticals LLC | 4 | $237 |
| Biotissue Holdings Inc. | 7 | $236 |
| Alcon | 4 | $229 |
| Novartis | 7 | $143 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $139 |
| Aerie Pharmaceuticals, Inc. | 1 | $116 |
| Johnson & Johnson Vision Care, Inc. | 1 | $115 |
| Thea Pharma Inc. | 4 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$583
- CEQUA$550
- MIEBO$331
- XIIDRA$331
- INFUSE$330
- iStent Inject Trabecular Micro-Bypass System$276
- RESTASIS$227
- LUMIGAN$225
- TYRVAYA$223
- Tobradex ST$200
- TRYPTYR$150
- GSW-iStentinjectWTrabecular Micro-Bypass System$138
- INVELTYS$124
- XDEMVY$121
- VUITY$121
- BIOTRUE ONE DAY$118
- BIOTRUE$116
- EYSUVIS$116
- Rhopressa$116
- Rocklatan$116
How this compares
$9,400 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $85,874 |
| XdemvyLotilaner | 23 | $43,436 |
| MieboPerfluorohexyloctane/Pf | 40 | $39,979 |
| LumiganBimatoprost | 69 | $37,472 |
| XiidraLifitegrast | 31 | $29,464 |
| TyrvayaVarenicline Tartrate | 33 | $23,145 |
| Cyclosporine | 40 | $22,548 |
| VevyeCyclosporine | 13 | $12,063 |
| CequaCyclosporine | 16 | $9,712 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $8,295 |
| Lotemax SmLoteprednol Etabonate | 24 | $6,130 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $5,675 |
| Timolol Maleate | 72 | $835 |
| Prednisolone Acetate | 12 | $688 |
| Latanoprost | 40 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,245 | $129,021175 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $2,791 | $69,44471 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $340 | $43,43623 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $496 | $23,14533 claims |
| Harrow Eye, LLCVevye | $379 | $12,06313 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,246 | $9,71216 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $808 | $6,13024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.
Other optometrist in Belleville
- Pamela LoweChicago$447K
- Jeffrey LewisChampaign$394K
- Adeyinka AdewaleGodfrey$391K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Steven EidenDeerfield$259K
- Peter KehoeGalesburg$167K
- Gulroop HansraDowners Grove$151K
- Treacy AdamoHinsdale$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.